Abstract
The bicuspid aortic valve (BAV), which is an aortic valve with two functional leaflets instead of the normal three, is the most common congenital heart valve abnormality accounting for a large number of valve replacements in the United States. Although bicuspid aortic valve disease (BAVD) is more common with age, it is not an inevitable consequence of aging. Tricuspid aortic valve disease (TAVD) (Rajamannan et al. 2003) appears to be an actively regulated disease process that cannot be characterized simply as “senile” or “degenerative.” BAVD covers a spectrum of disease from initial changes in the cell biology of the valve leaflets, through early calcification, tissue remodeling and aortic sclerosis, to outflow obstruction and aortic stenosis (Rajamannan 2011a). The later stages are characterized by fibrotic thickening of the valve leaflets and the formation of new blood vessels and calcium nodules – often including the formation of actual bone – throughout the valve leaflets but concentrated near the aortic surface. Epidemiological studies show that some of the risk factors for BAVD are similar to those for vascular atherosclerosis. Age, gender, and certain clinical factors are all associated with an increased risk of BAVD and TAVD. Clinical risk factors associated with the presence of BAVD include elevated low-density lipoprotein (LDL) cholesterol, but the association is relatively weak in those over 65 years old, the group at greatest risk of progressing to aortic stenosis. Other factors include smoking, hypertension, shorter height, lipoprotein (a) level, metabolic syndrome, type II diabetes, end-stage renal disease (but not mild to moderate renal disease), and imbalances in calcium or phosphate metabolism. However, the factors associated with disease initiation may differ from those that promote disease progression. Although aortic stenosis may occur in individuals with otherwise anatomically normal tricuspid aortic valves, congenital valve abnormalities markedly increase the risk as shown in Fig. 3.1. Nearly half of the individuals with aortic stenosis have a bicuspid aortic valve (BAV).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bonow RO, Carabello BA, Chatterjee K, de Leon Jr AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith Jr SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1–148.
Boyum J, Fellinger EK, Schmoker JD, Trombley L, McPartland K, Ittleman FP, Howard AB. Matrix metalloproteinase activity in thoracic aortic aneurysms associated with bicuspid and tricuspid aortic valves. J Thorac Cardiovasc Surg. 2004;127(3):686–91.
Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47(8):1707–12.
Cecconi M, Nistri S, Quarti A, Manfrin M, Colonna PL, Molini E, Perna GP. Aortic dilatation in patients with bicuspid aortic valve. J Cardiovasc Med. 2006;7(1):11–20.
Chandra S, Rajamannan NM, Sucosky P. Computational assessment of bicuspid aortic valve wall-shear stress: implications for calcific aortic valve disease. Biomech Model Mechanobiol. 2011. doi:10.1007/s10237-012-0375-x
Chandra S, Rajamannan NM, Sucosky P. Computational assessment of bicuspid aortic valve wall-shear stress: implications for calcific aortic valve disease. Biomech Model Mechanobiol. 2012. doi:10.1007/s10237-012-0375-x.
Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437(7056):270–4.
Lee TC, Zhao YD, Courtman DW, Stewart DJ. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation. 2000;101(20):2345–8.
Nistri S, Grande-Allen J, Noale M, Basso C, Siviero P, Maggi S, Crepaldi G, Thiene G. Aortic elasticity and size in bicuspid aortic valve syndrome. Eur Heart J. 2008;29(4):472–9.
Ortiz JT, Shin DD, Rajamannan NM. Approach to the patient with bicuspid aortic valve and ascending aorta aneurysm. Curr Treat Options Cardiovasc Med. 2006;8(6):461–7.
Rajamannan NM. Bicuspid aortic valve disease: the role of oxidative stress in Lrp5 bone formation. Cardiovasc Pathol. 2011a;20(3):168–76.
Rajamannan NM. The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory. J Cell Biochem. 2011b;112:2222–9.
Rajamannan NM. The role of Lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE(−/−)/Lrp5(−/−) mice. J Cell Biochem. 2011c; 112(10):2987–91.
Rajamannan NM. Oxidative-mechanical stress signals stem cell niche mediated Lrp5 osteogenesis in eNOS(−/−) null mice. J Cell Biochem. 2012;113(5): 1623–34.
Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype [see comment]. Circulation. 2003;107(17):2181–4.
Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation. 2005;112(9 Suppl):I229–34.
Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28(2):230–68.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Sucosky, P., Rajamannan, N.M. (2013). Bicuspid Aortic Valve Disease: From Bench to Bedside. In: Rajamannan, N. (eds) Cardiac Valvular Medicine. Springer, London. https://doi.org/10.1007/978-1-4471-4132-7_3
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4132-7_3
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4131-0
Online ISBN: 978-1-4471-4132-7
eBook Packages: MedicineMedicine (R0)